References
- National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Advancing progress in the workshop. Washington (DC): National Academies Press (US); 2019 July 1 [cited 2019 Sept 18]. Available from: www.ncbi.nlm.nih.gov/books/NBK544018/pdf/Bookshelf_NBK544018.pdf.
- Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15:1111–1122.
- Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol. 2015;13:e1002165.
- Good research practice in non-clinical pharmacology and biomedicine. In: editors, Bespalov A, Michel MC, Stecler T. Handbook of Experimental Pharmacology. Vol. 100. Berlin-Heidelberg: Spinger-Verlag; 2019 Forthcoming.
- European Quality In Preclinical Data (EQUID). [cited 2019 Sep 18]. Available from: https://quality-preclinical-data.eu/
- Innovative Medicine Initiatives. [cited 2019 Aug 6]. Available from: https://imi.europa.eu
- Hünig T. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. Febs J. 2016;283:3325–3334.
- Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161:512–526.
- Kenter MJ, Cohen AF. The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology. Br J Clin Pharmacol. 2015;79:545–547.
- Eddleston M, Cohen AF, Webb DJ. Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J Clin Pharmacol. 2016;81:582–586.
- van Gerven J, Cohen A. Integrating data from the investigational medicinal product dossier/investigator’s brochure. A new tool for translational integration of preclinical effects. Br J Clin Pharmacol. 2018;84:1457–1466.
- CHDR Center for Human Drug Research. [cited 2019 Sep 18]. Available from: www.ib-derisk.org and https://www.youtube.com/watch?v=6BJSbpYeKLo
- van Den Bogert CA, Cohen AF, Leufkens HGM, et al. Pharmacological vs. classical approaches in the design of first in man clinical drug trials. Br J Clin Pharmacol. 2017;83:2807–2812.
- U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005 [cited 2019 Sep 18]. Available from: https://www.fda.gov/media/72309/download
- European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products; Rev1 2018. [cited 2019 Sept 17]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf
- Breithaupt-Grögler K, Hardman T, de Hoon J, et al. The new first-in-human EMA guideline: disruptive or constructive? Outcomes from the first EUFEMED discussion forum. Front Pharmacol. 2019;10:398.
- Ministry of Health, Labour and Welfare.of Japan. Guidance for establishing safety in first-in-human studies during drug development; 2012 [cited 2019 Sep 18]. Available from: https://japan-guideline.org/wp-content/uploads/2018/08/MU021.pdf
- Instruction to authors. Meeting report. [cited 2019 Sep 18]. Available from: https://authorservices.taylorandfrancis.com/meeting-report/
- Otoshi T, Nagano T, Tachihara M, et al. Possible biomarkers for cancer immunotherapy. Cancers (Basel). 2019 Jul 3;11(7):E935.
- Lamberti MJ, Getz K Profiles of new approaches to improving the efficiency and performance of pharmaceutical drug development; 2015 [cited 2019 Sept 17]. Available from: http://csdd.tufts.edu/filesuploads/CSSD_PhRMAWhitePaper_FINAL.pdf
- PAASP. Partnership for assessment and accreditation of scientific practices. [cited 2019 Sep 18]. Available from: https://paasp.net/
- Cavero I, Guillon JM, Holzgrefe HH. Human organotypic bioconstructs from organ-on-chip devices for human-predictive biological insights on drug candidates. Expert Opin Drug Saf. 2019;18:651–677.